<DOC>
	<DOCNO>NCT00686088</DOCNO>
	<brief_summary>The purpose study determine therapeutic activity different concentration PRX302 increase volume and/or number deposit per gram prostate . Therapeutic activity determine base change PSA level , PSA velocity , PSA double time tumor burden follow treatment .</brief_summary>
	<brief_title>An Open-Label , Multi-Center , Phase IIa Trial PRX302 Treatment Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Completed full course radiation therapy prostate cancer least 2 year enrollment . Biochemical failure screening determine either ASTRO Phoenix definition . At least 5 available PSA reading completion radiation therapy prior screen . PSA level great 10 ng/mL . PSA double time least 9 month screen . Biopsyproven recurrent localized prostate cancer . Tumor stage T1C T2C . Prostate volume estimate 40 mL less determined TRUS . ECOG performance score 0 2 . Serum testosterone least 1 ng/dL . Prior history metastatic prostate cancer . Salvage external beam therapy and/or salvage brachytherapy prior enrollment . Biological , immunological , chemotherapeutic treatment cryotherapy complete radiation . Androgen ablation therapy within 12 month prior enrollment . Recurrence prostate cancer within 18 month definitive primary radiotherapy . Other medication prostate cancer . Presence active malignancy prostate cancer . Treatment investigational therapy within 12 month prior enrolment . Presence chronic indwelling Foley catheter obstructive uropathy . Previous transurethral resection prostate ( TURP ) , transurethral resection bladder neck , photoselective vaporization prostate ( PVP ) resection surgery urinary tract . Previous treatment PRX302 . Any evidence metastatic disease bone scan , CT magnetic resonance imaging ( MRI ) within 3 month prior enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>locally recurrent</keyword>
	<keyword>PRX302</keyword>
</DOC>